Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the recent TRITON3 Phase 3 Clinical Data of Rubraca (rucaparib) from Clovis Oncology for the Treatment of Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations.

Ticker(s): CLVS

Who's the expert?

Institution: Emory School of Medicine
Manages around 200 patients with metastatic castration-resistant prostate cancer (mCRPC).

Interview Goal

To gain insight into the potential use of Rubraca (rucaparib) in the treatment of metastatic Castration-Resistant Prostate Cancer with an emphasis on the recent release of phase 3 data from the TRITON3 clinical trial.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.